The report provides insights into the vaccines in the adult and adolescent vaccines market, including market forecasts up to 2018. It provides an in-depth analysis of the vaccines for the adult and adolescent market, as well as insights into the adult and adolescent vaccines market’s Research and Development (R&D) pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global adult and adolescent vaccines market. The report analyzes the market for adult and adolescent vaccines in the US, and the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. The report discusses the global pipeline for adult and adolescent vaccines across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research found that the adult and adolescent vaccines market in the top seven markets was valued at $7.2 billion in 2011, increasing at a Compound Annual Growth Rate (CAGR) of 6.9% during the 2007–2011 historic period. The market is projected to witness a growth of 5.6% during the 2011–2018 forecast period to reach $10.5 billion. The growth in the adult and adolescent vaccines market is driven by increased uptake of pneumococcal vaccines such as Prevnar 13 which got approved for use in people aged 50 and older. The pneumococcal vaccines market is expected to grow at a CAGR of 19% during the forecast period and reach $1.7 billion in 2018, from $0.5 billion in 2011.

Scope

• Annualized market data for the adult and adolescent vaccines market from 2007 to 2011, forecast forward to 2018
• Analysis of the adult and adolescent vaccines market in the leading geographies of the world, which includes the US, the UK, Germany, France, Italy, Spain, and Japan
• Market characterization of the adult and adolescent vaccines market including market size and cost of vaccination
• Key drivers and barriers that have a significant impact on the market
• Coverage of pipeline molecules in various phases of vaccine development
• Competitive benchmarking of leading companies. Key companies studied in this report are GlaxoSmithKline, Sanofi, Pfizer, Merck and Novartis.
• Key M&A activities and licensing agreements that have taken place between 2009 and up to November 2012 in the global adult and adolescent vaccines market.

Reasons to Buy

• Align your product portfolio to the markets with the highest growth potential
• Develop market-entry and market expansion strategies by identifying the potential regions and adult and adolescent vaccines market segments poised for strong growth
• Create a more specifically-tailored country strategy through the understanding of key drivers and barriers of the global adult and adolescent vaccines market
• Develop key strategic initiatives by understanding the key focus areas and top-selling products of leading companies
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

India Oncology Therapeutics Market

Oncology Therapeutics Market in India to 2018 – Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players’, which provides in-depth analysis of the key therapeutic indications of oncology, breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL), with forecasts until 2018. It also looks at treatment usage patterns and includes insights into the oncology R&D pipeline. The Indian oncology therapeutics market for breast cancer, lung cancer, colorectal cancer, prostate cancer and NHL was estimated to be worth $153.3m in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 12.7% from 2004. It is expected to reach $238.8m in 2018 at a CAGR of 6.5% from 2011. The slower growth in the forecast period is mainly due to the reduction in the price of leading marketed products for breast cancer, colorectal cancer, lung cancer and NHL after all 348 drugs on the National List of Essential Medicines (NLEM) are brought under price control regulations.

Carbon Fiber Global Market

Carbon Fiber Global Market to 2020 – Despite Price Concerns, Industrial Applications, Aerospace and Consumer Goods Drive Future Demand” is an in-depth report from GBI Research, which is focused on the demand side of the global carbon fiber industry. The report provides the reader with detailed analysis and forecasts of the major economic and market trends affecting global carbon fiber demand in the major regions of the world. It also provides analysis and description of the major drivers and restraints affecting carbon fiber demand in each region. Global carbon fiber demand is assessed in terms of end-user segments, prices and the competitive landscape, at both the regional and national level. Overall, the report presents a comprehensive analysis of the global carbon fiber market, covering all major parameters.